Cerenome (PSTV) Depreciation & Amortization (CF) (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Depreciation & Amortization (CF) of $96000.0 for Q1 2026, down 34.25% year-over-year from $146000.0 in Q1 2025, and down 33.79% quarter-over-quarter from $145000.0 in Q4 2025.
Cerenome (PSTV) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $96000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 34.25% year-over-year to $96000.0; the TTM figure through Mar 2026 stood at $395000.0 (down 54.23% YoY), while the FY2025 annual figure was $445000.0, down 48.97% from the prior year.
- Depreciation & Amortization (CF) declined to $96000.0 in Q1 2026 per PSTV's latest filing, from $145000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $348000.0 in Q4 2024 and bottomed at $77000.0 in Q2 2025.
- Historically, Depreciation & Amortization (CF) has averaged $156470.6 across 5 years, with a median of $155000.0 in 2022.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) surged 130.46% — and 2025, when it plunged 61.31%.
- Plus Therapeutics' Depreciation & Amortization (CF) stood at $159000.0 in 2022, then retreated by 5.03% to $151000.0 in 2023, then soared by 130.46% to $348000.0 in 2024, then tumbled by 58.33% to $145000.0 in 2025, then slumped by 33.79% to $96000.0 in 2026.
- Business Quant data shows PSTV's Depreciation & Amortization (CF) at $96000.0 in Q1 2026, $145000.0 in Q4 2025, and $77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 137,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96,000.00 |
| Mar 31, 2026 | 96,000.00 |
| Dec 31, 2025 | 145,000.00 |
| Dec 31, 2025 | 145,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Dec 31, 2023 | 151,000.00 |